Innovent Biologics, Inc. announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI310 in combination with sintilimab for the treatment of patients with recurrent or metastatic cervical cancer. The NMPA BTD for IBI310 was based on results from First part of a…
eTurboNews nkhani ndi za olembetsa okha. Kulembetsa ndi FREE.
Olembetsa amalowa pano Dinani apa kuti mulembetse KWAULERE
Olembetsa amalowa pano Dinani apa kuti mulembetse KWAULERE
ZOMWE MUNGACHITE PA NKHANIYI:
- adalengeza kuti Center for Drug Evaluation (CDE) ya National Medical Products Administration (NMPA) yaku China yapereka Breakthrough Therapy Designation (BTD) ya IBI310 kuphatikiza ndi sintilimab pochiza odwala omwe ali ndi khansa ya pachibelekero yobwereza kapena ya metastatic.
- The NMPA BTD for IBI310 was based on results from First part of a….
- eTurboNews nkhani ndi za olembetsa okha.
